Webinar

Overview of Key Results from the COMET-2 and -3 Phase 3 Pivotal Trials for Acoltremon, a TRPM8 Agonist

Wednesday, Dec 4, 2024 | 8:30 PM |

Time Zone (GMT +16:00)

Acoltremon ophthalmic solution 0.003% is an investigational drug candidate for dry eye disease. This webinar will provide an overview of the ocular neurosensory anatomy and physiology, the role of TRPM8 receptors on the ocular surface, and recent results from the COMET-2 and -3 Phase 3 clinical trials, which evaluated tear production and symptoms with acoltremon ophthalmic solution 0.003%, a TRPM8 agonist.

Educational Objective: Understand the

Ocular neurosensory anatomy and their general functions
Function and role of TRPM8 ion channels
Purpose, study design, and results from the COMET-2 and -3 Phase 3 clinical trials.

Preeya Gupta, MD

Moderator

Kelly Nichols, OD, MPH, PhD

Steve Pflugfelder, MD

Acoltremon ophthalmic solution 0.003% is an investigational drug that has not been approved for any indication in any country; therefore, its safety and efficacy have not been established.

*All faculty are paid consultants for Alcon.

Registration

Your Full Name*

Error: Please enter your full name.

Your Email*

Error: Please enter your email.

Phone Number

This field is required.

Street Address*

This field is required.

City*

Error: Your city is required.

State*

This field is required.

Postal / ZIP Code*

This field is required.

Country*

Error: Your country is required.

Registration Type*

This field is required.

Degree*

This field is required.

1. What percentage of your patients are being managed for dry eye?*

This field is required.

2. Why are you interested in learning about acoltremon?*

This field is required.

Marketing Permission

Yes, I consent to receiving emails*

Alcon - Medical Affairs Consent

Yes, I consent to receive communications from Alcon Global Medical Affairs*

Acoltremon ophthalmic solution 0.003% is an investigational drug that has not been approved for any indication in any country; therefore, its safety and efficacy have not been established.